Daval International has reported positive results from a Phase II study, evaluating the safety and tolerability of Aimspro as a monotherapy to treat patients with late-stage established diffuse cutaneous systemic sclerosis.
Twenty paitents were enrolled in the double-blind, randomised and placebo-controlled study. They were given either Aimspro or placebo, 4.5mg/ml subcutaneously, twice weekly for 26 weeks.
Go deeper with GlobalData
The primary endpoint was to assess the safety and tolerability of the drug through the 26-week period.
The secondary measures included investigating the efficacy of Aimspro as a therapeutic agent for scleroderma using inter alia the Scleroderma Health Assessment Questionnaire, the Modified Rodnan Skin Score, the Scleroderma UK Functional Score, the Patient and Physician Global Assessment, the SF-36 and the MRC Sum Score.
At the end of the study, Aimspro was found to be a safe and well-tolerated medication when administered to systemic sclerosis patients at a late-stage of the disease.
Aimspro treatment combines the benefits of polyclonal antibody technology with polypeptide components.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
